UBS Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,562
| Closed | -$1.09K | – | 10401 |
|
|
2023
Q4 | $1.09K | Buy |
1,562
+1,370
| +714% | +$795 | ﹤0.01% | 8404 |
|
|
2023
Q3 | $132 | Sell |
192
-94
| -33% | -$120 | ﹤0.01% | 8820 |
|
|
2023
Q2 | $689 | Sell |
286
-1,545
| -84% | -$6.6K | ﹤0.01% | 8132 |
|
|
2023
Q1 | $14.9K | Buy |
1,831
+1,246
| +213% | +$16.5K | ﹤0.01% | 7316 |
|
|
2022
Q4 | $6.96K | Buy |
+585
| New | +$6.69K | ﹤0.01% | 8960 |
|
|
2022
Q3 | – | Sell |
-1,228
| Closed | -$43K | – | 11254 |
|
|
2022
Q2 | $43K | Buy |
1,228
+276
| +29% | +$8.61K | ﹤0.01% | 6050 |
|
|
2022
Q1 | $39K | Sell |
952
-1,124
| -54% | -$48.2K | ﹤0.01% | 6747 |
|
|
2021
Q4 | $89K | Buy |
2,076
+1,362
| +191% | +$85K | ﹤0.01% | 6421 |
|
|
2021
Q3 | $49K | Sell |
714
-139
| -16% | -$10.2K | ﹤0.01% | 6360 |
|
|
2021
Q2 | $66K | Buy |
853
+139
| +19% | +$8.47K | ﹤0.01% | 6192 |
|
|
2021
Q1 | $47K | Sell |
714
-269
| -27% | -$21K | ﹤0.01% | 6636 |
|
|
2020
Q4 | $33K | Buy |
983
+841
| +592% | +$37.4K | ﹤0.01% | 6563 |
|
|
2020
Q3 | $8K | Sell |
142
-738
| -84% | -$43.8K | ﹤0.01% | 7055 |
|
|
2020
Q2 | $33K | Buy |
880
+713
| +427% | +$24.4K | ﹤0.01% | 6206 |
|
|
2020
Q1 | $4K | Sell |
167
-164
| -50% | -$6.96K | ﹤0.01% | 7429 |
|
|
2019
Q4 | $17K | Buy |
331
+242
| +272% | +$11.7K | ﹤0.01% | 7004 |
|
|
2019
Q3 | $5K | Buy |
89
+17
| +24% | +$1.22K | ﹤0.01% | 7504 |
|
|
2019
Q2 | $7K | Hold |
72
| – | – | ﹤0.01% | 7264 |
|
|
2019
Q1 | $11K | Hold |
72
| – | – | ﹤0.01% | 6768 |
|
|
2018
Q4 | $11K | Sell |
72
-50
| -41% | -$9.6K | ﹤0.01% | 7202 |
|
|
2018
Q3 | $30K | Sell |
122
-53
| -30% | -$12.5K | ﹤0.01% | 6552 |
|
|
2018
Q2 | $39K | Buy |
175
+80
| +84% | +$21.4K | ﹤0.01% | 6198 |
|
|
2018
Q1 | $23K | Buy |
95
+88
| +1,257% | +$23.1K | ﹤0.01% | 6320 |
|
|
2017
Q4 | $2K | Sell |
7
-23
| -77% | -$7.57K | ﹤0.01% | 7643 |
|
|
2017
Q3 | $11K | Buy |
30
+23
| +329% | +$8.16K | ﹤0.01% | 6844 |
|
|
2017
Q2 | $2K | Hold |
7
| – | – | ﹤0.01% | 7411 |
|
|
2017
Q1 | $2K | Sell |
7
-11
| -61% | -$2.78K | ﹤0.01% | 7319 |
|
|
2016
Q4 | $4K | Buy |
18
+11
| +157% | +$2.21K | ﹤0.01% | 7348 |
|
|
2016
Q3 | $2K | Hold |
7
| – | – | ﹤0.01% | 7434 |
|
|
2016
Q2 | $1K | Sell |
7
-1
| -13% | -$461 | ﹤0.01% | 7587 |
|
|
2016
Q1 | $3K | Buy |
+8
| New | +$2.86K | ﹤0.01% | 7219 |
|
|
2015
Q4 | – | Sell |
-12
| Closed | -$3K | – | 8637 |
|
|
2015
Q3 | $3K | Sell |
12
-36
| -75% | -$10K | ﹤0.01% | 7977 |
|
|
2015
Q2 | $14K | Buy |
+48
| New | +$14.5K | ﹤0.01% | 7203 |
|
Other funds holding DMK
UBS Group's DMK Position: Q1 2024 in Review
UBS Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 1,562 shares — an estimated $1.09K sold.
UBS Group first reported a position in DMK in Q2 2015 and held it in 33 quarters. The position peaked at $89K in Q4 2021. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.
- UBS Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 1,562 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $1.09K.
- UBS Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2015 and held it in 33 quarters.
- UBS Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $89K in Q4 2021.
- 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.